New drug candidate A3907 reverses liver disease in mice with multi-organ benefits

Researchers have demonstrated that A3907, an experimental cholestasis treatment, works across multiple organ systems to improve liver function in animal models. The findings suggest a promising pathway toward treating a debilitating condition that currently lacks effective therapies, potentially opening a significant market opportunity for hepatic disease management.

Originaltitel: A3907, a systemic ASBT inhibitor, improves cholestasis in mice by multiorgan activity and shows translational relevance to humans